Compare · MRK vs TMBR
MRK vs TMBR
Side-by-side comparison of Merck & Company Inc. (MRK) and Timber Pharmaceuticals Inc. (TMBR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and TMBR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK carries a market cap of $364.26B.
- MRK has hit the wire 21 times in the past 4 weeks while TMBR has been quiet.
- MRK has more recent analyst coverage (25 ratings vs 0 for TMBR).
- Company
- Merck & Company Inc.
- Timber Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $364.26B
- -
- 1M return
- +1.70%
- -
- 1Y return
- +58.97%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- 2015
- News (4w)
- 21
- 0
- Recent ratings
- 25
- 0
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Timber Pharmaceuticals Inc.
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical dermatology company, focused on the development and commercialization of treatments for orphan dermatologic diseases. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.
Latest MRK
- SEC Form 13F-HR filed by Merck & Company Inc.
- Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
- Merck to Participate in the Jefferies Global Healthcare Conference in London
- Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
- FDA Approval for WELIREG issued to MERCK SHARP DOHME
- SEC Form 10-Q filed by Merck & Company Inc.
- Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story
- SEC Form 4 filed by Director Diaz Paul J
- New insider Diaz Paul J claimed ownership of 296 shares (SEC Form 3)
- Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations
Latest TMBR
- Timber Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- Timber Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Bankruptcy or Receivership
- Timber Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Timber Pharmaceuticals Reveals Commencement Of NYSE American Delisting Proceedings: Common Stock Expected To Begin Trading On OTC Market
- Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market
- SEC Form 25-NSE filed by Timber Pharmaceuticals Inc.
- Timber Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Timber Pharmaceuticals Receives Court Approval Of All "First Day" Motions To Support Business Operations & Discloses Communication From NYSE American
- Timber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE American
- Timber Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Termination of a Material Definitive Agreement, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits